CA1327358C
(en)
|
1987-11-17 |
1994-03-01 |
Morio Fujiu |
Fluoro cytidine derivatives
|
JP3040121B2
(ja)
*
|
1988-01-12 |
2000-05-08 |
ジェネンテク,インコーポレイテッド |
増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
|
CA2045231A1
(en)
*
|
1990-07-19 |
1992-01-20 |
Victor Ling |
Cell membrane glycoprotein correlated with resistance to platinum-containing antineoplastic agents
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
AU671491B2
(en)
|
1992-12-18 |
1996-08-29 |
F. Hoffmann-La Roche Ag |
N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
|
TW254946B
(hu)
|
1992-12-18 |
1995-08-21 |
Hoffmann La Roche |
|
US5362718A
(en)
*
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
ZA956029B
(en)
|
1994-07-22 |
1997-01-20 |
Lilly Co Eli |
Combination treatment for inhibiting bone loss
|
US5476932A
(en)
|
1994-08-26 |
1995-12-19 |
Hoffmann-La Roche Inc. |
Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
US6267958B1
(en)
*
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
JP3437685B2
(ja)
*
|
1995-09-12 |
2003-08-18 |
株式会社東芝 |
交直変換装置の制御保護システム
|
JP4009681B2
(ja)
|
1995-11-07 |
2007-11-21 |
キリンファーマ株式会社 |
血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
US6002008A
(en)
*
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
US6426383B1
(en)
*
|
1997-05-28 |
2002-07-30 |
Nalco Chemical Company |
Preparation of water soluble polymer dispersions from vinylamide monomers
|
US6251912B1
(en)
|
1997-08-01 |
2001-06-26 |
American Cyanamid Company |
Substituted quinazoline derivatives
|
SE9704545D0
(sv)
*
|
1997-12-05 |
1997-12-05 |
Astra Pharma Prod |
Novel compounds
|
US6297258B1
(en)
*
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
EA004436B1
(ru)
|
1998-09-29 |
2004-04-29 |
Уайт Холдингз Корпорейшн |
Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
|
US6288082B1
(en)
*
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
US6432979B1
(en)
*
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
US6277983B1
(en)
*
|
2000-09-27 |
2001-08-21 |
American Home Products Corporation |
Regioselective synthesis of rapamycin derivatives
|
TWI256395B
(en)
|
1999-09-29 |
2006-06-11 |
Wyeth Corp |
Regioselective synthesis of rapamycin derivatives
|
CZ20022332A3
(cs)
|
2000-01-07 |
2003-01-15 |
Transform Pharmaceuticals, Inc. |
Sestava vzorků
|
US6384051B1
(en)
|
2000-03-13 |
2002-05-07 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps
|
TWI310684B
(en)
*
|
2000-03-27 |
2009-06-11 |
Bristol Myers Squibb Co |
Synergistic pharmaceutical kits for treating cancer
|
GB0008368D0
(en)
*
|
2000-04-06 |
2000-05-24 |
Astrazeneca Ab |
Combination product
|
US7306801B2
(en)
*
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
DK1318837T3
(da)
*
|
2000-08-11 |
2005-01-10 |
Wyeth Corp |
Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom
|
TWI286074B
(en)
*
|
2000-11-15 |
2007-09-01 |
Wyeth Corp |
Pharmaceutical composition containing CCI-779 as an antineoplastic agent
|
AR042586A1
(es)
*
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
BR0208627A
(pt)
|
2001-04-06 |
2004-03-09 |
Wyeth Corp |
Combinações antineoplásicas tal como rapamicina junto com gencitabina ou fluorouracila
|
TWI233359B
(en)
*
|
2001-04-06 |
2005-06-01 |
Wyeth Corp |
Pharmaceutical composition for treating neoplasm
|
TWI296196B
(en)
*
|
2001-04-06 |
2008-05-01 |
Wyeth Corp |
Antineoplastic combinations
|
US20020198137A1
(en)
*
|
2001-06-01 |
2002-12-26 |
Wyeth |
Antineoplastic combinations
|
NZ529877A
(en)
|
2001-06-01 |
2006-08-31 |
Wyeth Corp |
Antineoplastic combinations
|
AU2002345670A1
(en)
|
2001-06-14 |
2003-01-02 |
The Regents Of The University Of California |
Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
|
UA77200C2
(en)
*
|
2001-08-07 |
2006-11-15 |
Wyeth Corp |
Antineoplastic combination of cci-779 and bkb-569
|
CN1659145A
(zh)
|
2001-11-27 |
2005-08-24 |
惠氏控股公司 |
作为egf-r和her2激酶抑制剂的3-氰基喹啉
|
IL162734A0
(en)
*
|
2002-02-01 |
2005-11-20 |
Ariad Gene Therapeutics Inc |
Phosphorus-containing compounds & uses thereof
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
AU2003247483A1
(en)
*
|
2002-05-30 |
2003-12-31 |
The Children's Hospital Of Philadelphia |
Methods for treatment of acute lymphocytic leukemia
|
US7384940B2
(en)
*
|
2002-06-05 |
2008-06-10 |
Cedars-Sinai Medical Center |
Method of treating cancer using kinase inhibitors
|
AU2003248813A1
(en)
|
2002-07-05 |
2004-01-23 |
Beth Israel Deaconess Medical Center |
Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
|
AU2003256847A1
(en)
*
|
2002-07-26 |
2004-02-16 |
Advanced Research And Technology Institute At Indiana University |
Method of treating cancer
|
AU2003258061A1
(en)
*
|
2002-08-02 |
2004-02-23 |
Salmedix, Inc. |
Therapeutic inhibitionof protein kinases in cancer cells
|
US20040209930A1
(en)
*
|
2002-10-02 |
2004-10-21 |
Carboni Joan M. |
Synergistic methods and compositions for treating cancer
|
CL2004000016A1
(es)
|
2003-01-21 |
2005-04-15 |
Wyeth Corp |
Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
|
EP1594504A4
(en)
*
|
2003-01-23 |
2008-12-17 |
T K Signal Ltd |
NEW IRREVERSIBLE EGF RECEPTOR TYROSINE KINASE INHIBITORS AND THEIR USES FOR THERAPEUTIC AND DIAGNOSTIC PURPOSES
|
CN1437942A
(zh)
|
2003-02-08 |
2003-08-27 |
杭州华卫制药技术开发有限公司 |
注射用长春瑞滨粉针剂及制备方法
|
UA83484C2
(uk)
|
2003-03-05 |
2008-07-25 |
Уайт |
Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
|
RU2005136222A
(ru)
|
2003-04-22 |
2006-03-20 |
Уайт (Us) |
Противоопухолевые комбинации
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
DE602004010407T2
(de)
|
2003-07-23 |
2008-10-16 |
Bayer Pharmaceuticals Corp., West Haven |
Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
|
US20050025825A1
(en)
|
2003-07-31 |
2005-02-03 |
Xanodyne Pharmacal, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
CN1832757A
(zh)
|
2003-08-01 |
2006-09-13 |
惠氏控股公司 |
表皮生长因子受体激酶抑制剂与细胞毒性剂组合在治疗和抑制癌症中的用途
|
MXPA06001590A
(es)
|
2003-08-19 |
2006-05-19 |
Wyeth Corp |
Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos.
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
AU2003304497B2
(en)
|
2003-09-15 |
2010-06-24 |
Wyeth Llc |
Substituted quinolines as protein tyrosine kinase enzyme inhibitors
|
TWI372066B
(en)
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
US20050142192A1
(en)
|
2003-10-15 |
2005-06-30 |
Wyeth |
Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
|
WO2005049021A1
(en)
|
2003-11-03 |
2005-06-02 |
Oy Helsinki Transplantation R & D Ltd |
Materials and methods for inhibiting neointimal hyperplasia
|
EP1756137A4
(en)
|
2003-11-05 |
2007-10-31 |
Univ Texas |
DIAGNOSTIC AND THERAPEUTIC PROCEDURES AND COMPOSITIONS CONCERNING PTEN AND BREAST CANCER
|
AR046639A1
(es)
|
2003-11-21 |
2005-12-14 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti- igfr1
|
US7235564B2
(en)
*
|
2003-12-04 |
2007-06-26 |
Amr Technology, Inc. |
Vinorelbine derivatives
|
US9016221B2
(en)
|
2004-02-17 |
2015-04-28 |
University Of Florida Research Foundation, Inc. |
Surface topographies for non-toxic bioadhesion control
|
AR047988A1
(es)
*
|
2004-03-11 |
2006-03-15 |
Wyeth Corp |
Combinaciones antineoplásicas de cci-779 y rituximab
|
CN104774931B
(zh)
*
|
2004-03-31 |
2017-11-10 |
综合医院公司 |
测定癌症对表皮生长因子受体靶向性治疗反应性的方法
|
DK1748998T3
(da)
|
2004-05-28 |
2010-05-10 |
Hetero Drugs Ltd |
Ny stereoselektiv syntese af benzimidazolsulfoxider
|
WO2005118876A2
(en)
*
|
2004-06-04 |
2005-12-15 |
Genentech, Inc. |
Egfr mutations
|
MX2007000944A
(es)
|
2004-07-23 |
2007-04-13 |
Astrazeneca Ab |
Metodo para pronosticar la sensibilidad de un tumor a farmacos del receptor erbb.
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
TW200616612A
(en)
|
2004-10-08 |
2006-06-01 |
Wyeth Corp |
Method for the teatment of polycystic kidney disease field of invention
|
GT200500287A
(es)
|
2004-10-13 |
2006-04-17 |
|
Analogos de 17-hidroxiwortmanina como inhibidores de pi3k
|
WO2006044748A2
(en)
|
2004-10-15 |
2006-04-27 |
Monogram Biosciences, Inc. |
RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
|
US20060084666A1
(en)
*
|
2004-10-18 |
2006-04-20 |
Harari Paul M |
Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
|
US20080268034A1
(en)
|
2005-01-07 |
2008-10-30 |
Girish Karanth |
Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
|
GB0501999D0
(en)
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
ZA200706804B
(en)
|
2005-02-03 |
2008-10-29 |
Gen Hospital Corp |
Method for treating gefitinib resistant cancer
|
WO2006081985A1
(en)
|
2005-02-04 |
2006-08-10 |
F. Hoffmann-La Roche Ag |
Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
|
EP1851243A2
(en)
|
2005-02-24 |
2007-11-07 |
Amgen, Inc. |
Epidermal growth factor receptor mutations
|
CN101163468A
(zh)
|
2005-02-28 |
2008-04-16 |
卫材R&D管理有限公司 |
磺酰胺化合物的新联合用途
|
WO2006093353A1
(ja)
|
2005-03-03 |
2006-09-08 |
Takeda Pharmaceutical Company Limited |
放出制御組成物
|
US8105768B2
(en)
|
2005-03-09 |
2012-01-31 |
Abbott Laboratories |
Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number
|
GB0504994D0
(en)
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
US20060235006A1
(en)
|
2005-04-13 |
2006-10-19 |
Lee Francis Y |
Combinations, methods and compositions for treating cancer
|
WO2006113151A2
(en)
*
|
2005-04-14 |
2006-10-26 |
Wyeth |
Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients
|
WO2006116016A2
(en)
|
2005-04-21 |
2006-11-02 |
The Regents Of The University Of California |
Molecular determinants of egfr kinase inhibitor response in glioblastoma
|
WO2006116514A2
(en)
|
2005-04-28 |
2006-11-02 |
Wyeth |
Micronized tanaproget, compositions, and methods of preparing the same
|
RU2007141654A
(ru)
|
2005-05-12 |
2009-05-20 |
Пфайзер Инк. (US) |
Противоопухолевая комбинированная терапия, в которой используется сунитиниб-малат
|
AU2006249600A1
(en)
|
2005-05-25 |
2006-11-30 |
Wyeth |
Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
|
WO2006127205A2
(en)
*
|
2005-05-25 |
2006-11-30 |
Wyeth |
Methods of preparing 3-cyano-quinolines and intermediates made thereby
|
DE102005053679A1
(de)
|
2005-06-24 |
2006-12-28 |
Bayer Healthcare Ag |
Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
|
MX2008000666A
(es)
|
2005-07-15 |
2008-03-13 |
Wyeth Corp |
Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato.
|
EP1925941B1
(en)
|
2005-08-01 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
US9006240B2
(en)
|
2005-08-02 |
2015-04-14 |
Eisai R&D Management Co., Ltd. |
Method for assay on the effect of vascularization inhibitor
|
NZ566387A
(en)
|
2005-10-05 |
2010-05-28 |
Astrazeneca Uk Ltd |
Method to predict or monitor the response of a patient to an ErbB receptor drug by screening for mutations in an ErbB receptor
|
US20110052570A1
(en)
|
2005-10-26 |
2011-03-03 |
Children's Medical Center Corporation |
Method to prognose response to anti-egfr therapeutics
|
PE20071042A1
(es)
*
|
2005-11-04 |
2007-10-12 |
Wyeth Corp |
Producto farmaceutico que comprende temsirolimus y malato de sunitinib
|
PE20070763A1
(es)
|
2005-11-04 |
2007-08-08 |
Wyeth Corp |
COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
|
EP2340837B1
(en)
|
2005-11-11 |
2017-03-15 |
Boehringer Ingelheim International GmbH |
Combination treatment of cancer comprising egfr/her2 inhibitors
|
CA2630833C
(en)
|
2005-11-24 |
2015-01-06 |
Aicuris Gmbh & Co. Kg |
Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer
|
JP2007145745A
(ja)
|
2005-11-25 |
2007-06-14 |
Osaka Univ |
変異型EGFR下流シグナルを抑制するSrcファミリーチロシンキナーゼ阻害剤を含む肺癌治療剤およびその利用
|
WO2007075794A2
(en)
|
2005-12-22 |
2007-07-05 |
Wyeth |
Oral formulations comprising tigecycline
|
WO2007095038A2
(en)
|
2006-02-09 |
2007-08-23 |
Novartis Ag |
Mutations and polymorphisms of erbb2
|
US20100152198A1
(en)
|
2006-04-07 |
2010-06-17 |
Manley Paul W |
Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
|
TW200806282A
(en)
|
2006-05-05 |
2008-02-01 |
Wyeth Corp |
Solid dosage formulations
|
EP3399450A1
(en)
|
2006-05-18 |
2018-11-07 |
Caris MPI, Inc. |
System and method for determining individualized medical intervention for a disease state
|
TW200808728A
(en)
|
2006-05-23 |
2008-02-16 |
Wyeth Corp |
Method of preparing 4-halogenated quinoline intermediates
|
ES2427924T3
(es)
|
2006-06-30 |
2013-11-04 |
Merck Sharp & Dohme Corp. |
Biomarcador IGFBP2
|
RU2492864C2
(ru)
|
2006-09-18 |
2013-09-20 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Способ лечения рака, несущего мутации egfr
|
EP2077819A4
(en)
|
2006-09-28 |
2011-05-25 |
Follica Inc |
METHODS, MATERIALS, AND COMPOSITIONS FOR GENERATING NEW CELLULAR FOLLICLES AND PUSHING HAIR
|
US20090317456A1
(en)
|
2006-10-13 |
2009-12-24 |
Medigene Ag |
Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
|
CA2672828A1
(en)
|
2006-12-13 |
2008-06-26 |
Schering Corporation |
Methods of treatment
|
US20100143340A1
(en)
|
2006-12-13 |
2010-06-10 |
Schering Corporation |
Methods and compositions for treating cancer
|
CN111643496A
(zh)
|
2006-12-14 |
2020-09-11 |
埃克塞利希斯股份有限公司 |
使用mek抑制剂的方法
|
WO2008076143A1
(en)
|
2006-12-18 |
2008-06-26 |
Osi Pharmaceuticals, Inc. |
Combination of igfr inhibitor and anti-cancer agent
|
EP2124951B1
(en)
|
2006-12-21 |
2014-05-21 |
Vertex Pharmaceuticals Inc. |
5-cyan0-4- (pyrrolo[2, 3b]pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
|
CN101631536A
(zh)
|
2007-01-12 |
2010-01-20 |
惠氏公司 |
片中片组合物
|
CN104043123B
(zh)
|
2007-01-25 |
2019-08-13 |
达娜-法勃肿瘤研究所公司 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
WO2008093878A1
(en)
|
2007-02-01 |
2008-08-07 |
Takeda Pharmaceutical Company Limited |
Tablet preparation without causing a tableting trouble
|
WO2008121467A2
(en)
|
2007-02-28 |
2008-10-09 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for treating cancer
|
GB0706633D0
(en)
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
Combination
|
EP1978106A1
(en)
|
2007-04-07 |
2008-10-08 |
Universitätsklinikum Hamburg-Eppendorf |
Detection of ESR1 amplification in endometrium cancer and ovary cancer
|
AU2008239594B2
(en)
|
2007-04-13 |
2013-10-24 |
Beth Israel Deaconess Medical Center |
Methods for treating cancer resistant to ErbB therapeutics
|
CN101663584A
(zh)
|
2007-04-19 |
2010-03-03 |
威尔斯达特生物制剂公司 |
未分离的循环癌细胞的Her-2/neu蛋白的检测和治疗
|
WO2008136838A1
(en)
|
2007-05-04 |
2008-11-13 |
Trustees Of Dartmouth College |
Novel amide derivatives of cddo and methods of use thereof
|
WO2009005673A1
(en)
|
2007-06-28 |
2009-01-08 |
Schering Corporation |
Anti-igf1r
|
ES2584904T3
(es)
|
2007-09-10 |
2016-09-30 |
Boston Biomedical, Inc. |
Nuevas composiciones y métodos para el tratamiento del cáncer
|
EP2205076A4
(en)
|
2007-09-24 |
2010-12-29 |
Tragara Pharmaceuticals Inc |
POLYTHERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DOUBLE INHIBITORS OF EGFR ÝERBB1 AND HER-2 ÝERBB2
|
US8022216B2
(en)
*
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
CN101918579A
(zh)
|
2007-10-22 |
2010-12-15 |
先灵公司 |
完全人抗-vegf抗体和使用方法
|
BRPI0819218A2
(pt)
|
2007-11-05 |
2015-05-05 |
Puretech Ventures |
Métodos, estojos e composições para administração de compostos farmacêuticos
|
CN101185633A
(zh)
|
2007-12-14 |
2008-05-28 |
山东蓝金生物工程有限公司 |
一种治疗实体肿瘤的尼拉替尼缓释植入剂
|
MX2010006854A
(es)
|
2007-12-18 |
2010-09-09 |
Schering Corp |
Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
|
US20100297118A1
(en)
|
2007-12-27 |
2010-11-25 |
Macdougall John |
Therapeutic Cancer Treatments
|
WO2009100176A2
(en)
|
2008-02-07 |
2009-08-13 |
Abbott Laboratories |
Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
|
WO2009105234A2
(en)
|
2008-02-19 |
2009-08-27 |
Combinatorx, Incorporated |
Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
|
ES2398618T3
(es)
|
2008-02-25 |
2013-03-20 |
Nestec S.A. |
Selección de fármacos para terapia del cáncer de mama utilizando matrices de anticuerpos
|
WO2009111073A2
(en)
|
2008-03-06 |
2009-09-11 |
Odyssey Thera, Inc. |
High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
|
WO2009142810A2
(en)
|
2008-03-25 |
2009-11-26 |
Schering Corporation |
Methods for treating or preventing colorectal cancer
|
EP2279267A4
(en)
|
2008-03-27 |
2012-01-18 |
Vascular Biosciences Inc |
METHOD FOR IDENTIFICATION OF NEW THERAPEUTIC CANDIDATES VIA GENE EXPRESSION ANALYSIS IN VASCULAR DISEASES
|
US20090246198A1
(en)
|
2008-03-31 |
2009-10-01 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
WO2009126662A1
(en)
|
2008-04-08 |
2009-10-15 |
Syndax Pharmaceuticals, Inc. |
Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
|
AU2009237578C1
(en)
|
2008-04-18 |
2014-12-04 |
Reata Pharmaceuticals, Inc. |
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
|
NZ588710A
(en)
|
2008-04-18 |
2012-12-21 |
Reata Pharmaceuticals Inc |
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
|
US8071632B2
(en)
|
2008-04-18 |
2011-12-06 |
Reata Pharmaceuticals, Inc. |
Antioxidant inflammation modulators: novel derivatives of oleanolic acid
|
PL2271658T3
(pl)
|
2008-04-18 |
2017-05-31 |
Reata Pharmaceuticals, Inc. |
Przeciwutleniające modulatory zapalenia: c-17 homologowane pochodne kwasu oleanolowego
|
MX339476B
(es)
|
2008-04-18 |
2016-05-27 |
Reata Pharmaceuticals Inc |
Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
|
MX2010012064A
(es)
|
2008-05-05 |
2010-12-06 |
Schering Corp |
Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
ES2531322T3
(es)
|
2008-06-17 |
2015-03-13 |
Wyeth Llc |
Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
|
EP2309860B1
(en)
|
2008-07-22 |
2014-01-08 |
Trustees of Dartmouth College |
Monocyclic cyanoenones and methods of use thereof
|
PL2326329T3
(pl)
|
2008-08-04 |
2017-07-31 |
Wyeth Llc |
Przeciwnowotworowe połączenia 4-anilino-3-cyjanochinolin i kapecytabiny
|
US20100069340A1
(en)
|
2008-09-11 |
2010-03-18 |
Wyeth |
Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
|
EP2347009A4
(en)
|
2008-10-14 |
2012-05-30 |
Caris Mpi Inc |
GENE AND GENE EXPRESSED TARGET PROTEINS FOR THE PRESENTATION OF BIOMARKERS AND SIGNATURES BY TUMOR TYPE
|
WO2010048477A2
(en)
|
2008-10-24 |
2010-04-29 |
Wyeth Llc |
Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
|
MX2011004869A
(es)
|
2008-11-07 |
2011-06-20 |
Santaris Pharma As |
Terapia de combinacion selectiva de erbb-3 (her3).
|
WO2010085845A1
(en)
|
2009-01-28 |
2010-08-05 |
The University Of Queensland |
Cancer therapy and/or diagnosis
|
KR20110113648A
(ko)
|
2009-02-04 |
2011-10-17 |
바이파 사이언스 인코포레이티드 |
Parp 억제제와 함께 성장인자 억제제를 사용한 폐암의 치료
|
WO2010098627A2
(ko)
|
2009-02-27 |
2010-09-02 |
한올바이오파마주식회사 |
약제학적 제제
|
EP3031807A1
(en)
|
2009-03-11 |
2016-06-15 |
Auckland UniServices Limited |
Prodrug forms of kinase inhibitors and their use in therapy
|
WO2010117633A1
(en)
|
2009-04-06 |
2010-10-14 |
Wyeth Llc |
Treatment regimen utilizing neratinib for breast cancer
|
AR076053A1
(es)
|
2009-04-14 |
2011-05-18 |
Schering Corp |
Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
US9908884B2
(en)
|
2009-05-05 |
2018-03-06 |
Dana-Farber Cancer Institute, Inc. |
EGFR inhibitors and methods of treating disorders
|
SG177309A1
(en)
|
2009-07-02 |
2012-02-28 |
Wyeth Llc |
3-cyanoquinoline tablet formulations and uses thereof
|
KR20110007985A
(ko)
|
2009-07-17 |
2011-01-25 |
한올바이오파마주식회사 |
N,n―디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
KR20110007984A
(ko)
|
2009-07-17 |
2011-01-25 |
한올바이오파마주식회사 |
N,n―디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
WO2011025269A2
(ko)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
WO2011025271A2
(ko)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
KR20110021691A
(ko)
|
2009-08-25 |
2011-03-04 |
한올바이오파마주식회사 |
메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
US20110055838A1
(en)
|
2009-08-28 |
2011-03-03 |
Moyes William A |
Optimized thread scheduling via hardware performance monitoring
|
CN102665756A
(zh)
|
2009-10-01 |
2012-09-12 |
Csl有限公司 |
费城染色体阳性白血病的治疗方法
|
EP2498751B1
(en)
|
2009-11-09 |
2019-04-03 |
Wyeth LLC |
Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
|
EP3566697A1
(en)
|
2009-11-09 |
2019-11-13 |
Wyeth LLC |
Tablet formulations of neratinib maleate
|
CN105999263B
(zh)
|
2009-11-13 |
2021-06-29 |
第一三共欧洲有限公司 |
用于治疗或预防人表皮生长因子受体-3(her-3)相关疾病的材料和方法
|
JP2013512882A
(ja)
|
2009-12-07 |
2013-04-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
トリプルネガティブ乳癌の治療に使用するbibw2992
|
EP3575413A1
(en)
|
2009-12-11 |
2019-12-04 |
Wyeth LLC |
Phosphatidylinositol-3-kinase pathway biomarkers
|
EP2524231B1
(en)
|
2010-01-13 |
2017-06-28 |
Wyeth LLC |
A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR
|